163 related articles for article (PubMed ID: 37960235)
1. Effects of Dietary Supplementation with a Ferulic Acid-Rich Bioactive Component of Wheat Bran in a Murine Model of Graft-Versus-Host Disease.
Preciado S; Martínez-Villaluenga C; Rico D; Muntión S; García-Macías MC; Navarro-Bailón A; Martín-Diana AB; Sánchez-Guijo F
Nutrients; 2023 Oct; 15(21):. PubMed ID: 37960235
[TBL] [Abstract][Full Text] [Related]
2. Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.
Theurich S; Fischmann H; Shimabukuro-Vornhagen A; Chemnitz JM; Holtick U; Scheid C; Skoetz N; von Bergwelt-Baildon M
Cochrane Database Syst Rev; 2012 Sep; (9):CD009159. PubMed ID: 22972135
[TBL] [Abstract][Full Text] [Related]
3. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
[TBL] [Abstract][Full Text] [Related]
4. Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study.
Yeshurun M; Shpilberg O; Herscovici C; Shargian L; Dreyer J; Peck A; Israeli M; Levy-Assaraf M; Gruenewald T; Mechoulam R; Raanani P; Ram R
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1770-5. PubMed ID: 26033282
[TBL] [Abstract][Full Text] [Related]
5. Treatment with a rho kinase inhibitor improves survival from graft-versus-host disease in mice after MHC-haploidentical hematopoietic cell transplantation.
Iyengar S; Zhan C; Lu J; Korngold R; Schwartz DH
Biol Blood Marrow Transplant; 2014 Aug; 20(8):1104-11. PubMed ID: 24796280
[TBL] [Abstract][Full Text] [Related]
6. The A
Geraghty NJ; Adhikary SR; Watson D; Sluyter R
Int Immunopharmacol; 2019 Jul; 72():479-486. PubMed ID: 31051404
[TBL] [Abstract][Full Text] [Related]
7. Insights into mechanisms of graft-versus-host disease through humanised mouse models.
Elhage A; Sligar C; Cuthbertson P; Watson D; Sluyter R
Biosci Rep; 2022 Sep; 42(9):. PubMed ID: 35993192
[TBL] [Abstract][Full Text] [Related]
8. Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration.
Gao Y; Shan W; Gu T; Zhang J; Wu Y; Li X; Zeng X; Zhou H; Chen Z; Xiao H
Front Immunol; 2021; 12():785774. PubMed ID: 34987512
[TBL] [Abstract][Full Text] [Related]
9. PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Ry
Burger DR; Parker Y; Guinta K; Lindner D
Biol Blood Marrow Transplant; 2018 Feb; 24(2):260-266. PubMed ID: 29128556
[TBL] [Abstract][Full Text] [Related]
10. Post Transplantation Bilirubin Nanoparticles Ameliorate Murine Graft Versus Host Disease
Pareek S; Flegle AS; Boagni D; Kim JY; Yoo D; Trujillo-Ocampo A; Lee SE; Zhang M; Jon S; Im JS
Front Immunol; 2022; 13():893659. PubMed ID: 35720391
[TBL] [Abstract][Full Text] [Related]
11. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
12. BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT.
Copsel SN; Lightbourn CO; Barreras H; Lohse I; Wolf D; Bader CS; Manov J; Kale BJ; Shah D; Brothers SP; Perez VL; Komanduri KV; Wahlestedt C; Levy RB
Front Immunol; 2018; 9():3104. PubMed ID: 30733722
[TBL] [Abstract][Full Text] [Related]
13. The Green Tea Catechin Epigallocatechin Gallate Ameliorates Graft-versus-Host Disease.
Westphal S; McGeary A; Rudloff S; Wilke A; Penack O
PLoS One; 2017; 12(1):e0169630. PubMed ID: 28103249
[TBL] [Abstract][Full Text] [Related]
14. Role of tumor necrosis factor-alpha in graft-versus-host disease and graft-versus-leukemia responses.
Korngold R; Marini JC; de Baca ME; Murphy GF; Giles-Komar J
Biol Blood Marrow Transplant; 2003 May; 9(5):292-303. PubMed ID: 12766879
[TBL] [Abstract][Full Text] [Related]
15. Increased splenic human CD4
Geraghty NJ; Belfiore L; Adhikary SR; Alexander SI; Sluyter R; Watson D
Transpl Immunol; 2019 Jun; 54():38-46. PubMed ID: 30743002
[TBL] [Abstract][Full Text] [Related]
16. Combination of anti-CD4 antibody treatment and donor lymphocyte infusion ameliorates graft-versus-host disease while preserving graft-versus-tumor effects in murine allogeneic hematopoietic stem cell transplantation.
Ueha S; Yokochi S; Ishiwata Y; Kosugi-Kanaya M; Shono Y; Shibayama S; Ito S; Matsushima K
Cancer Sci; 2017 Oct; 108(10):1967-1973. PubMed ID: 28787768
[TBL] [Abstract][Full Text] [Related]
17. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
[TBL] [Abstract][Full Text] [Related]
18. Flagellin, a TLR5 agonist, reduces graft-versus-host disease in allogeneic hematopoietic stem cell transplantation recipients while enhancing antiviral immunity.
Hossain MS; Jaye DL; Pollack BP; Farris AB; Tselanyane ML; David E; Roback JD; Gewirtz AT; Waller EK
J Immunol; 2011 Nov; 187(10):5130-40. PubMed ID: 22013117
[TBL] [Abstract][Full Text] [Related]
19. Early administration of lenalidomide after allogeneic hematopoietic stem cell transplantation suppresses graft-versus-host disease by inhibiting T-cell migration to the gastrointestinal tract.
Tsubokura Y; Yoshimura H; Satake A; Nasa Y; Tsuji R; Ito T; Nomura S
Immun Inflamm Dis; 2022 Sep; 10(9):e688. PubMed ID: 36039651
[TBL] [Abstract][Full Text] [Related]
20. Ixazomib suppresses human dendritic cell and modulates murine graft-versus-host disease in a schedule-dependent fashion.
Al-Homsi AS; Goodyke A; Cole K; Muilenburg M; McLane M; Abdel-Mageed S; Feng Y
Exp Hematol; 2017 Apr; 48():50-57. PubMed ID: 28007655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
